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Neurotransmitter Receptors – A Unique
Pathway of Neuro-Immune Interactions
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Abstract. Circulating autoantibodies directed against receptors of various autonomic neurotransmitters, including the muscarinic
and nicotinic ganglionic acetylcholine-receptor and the beta-1-adrenergic receptor have been detected in patients with various
autoimmune diseases. These antibodies have been hypothesised to have a direct influence on the function of the target organ,
including exocrine glandular function, smooth muscle or myocardium contractility. The potential immune-mediated function-
modifying interaction between the immune and the autonomic nervous system has inspired interesting experiments. These
studies have explored unique pathways whereby autoantibodies may alter the cellular and tissue homeostasis leading to organ
damage. The present review summarises these results, with particular focus on anti-muscarinic receptor antibodies in Sjo¨gren’s
syndrome, and highlights the difficulties in the detection of anti-neurotransmitter receptor antibodies.
INTRODUCTION
Autoantibodies that react with postsynaptic recep-
tors of autonomic nervous system neurotransmitters
have increasingly attracted attention in the past few
years. These include antibodies to various muscarinic
acetylcholine-receptor (mAChR) subtypes, ganglionic
nicotinic receptors and beta-1-adrenergic receptors.
These autoantibodies are supposed to modulate the
function of the involved organs by means of interfer-
ing with the autonomic neurotransmission. Long-term
effects of this interaction may lead to the depriva-
tion of autonomic neural stimuli that may result in
profound structural remodelling of the target organs.
The present review focuses on the functional and
immunodiagnostic properties of anti-mAChR autoan-
tibodies in systemic autoimmune diseases, in particular
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in Sjo¨gren’s syndrome (SS) and will provide an outlook
into further diseases affected by autonomic neurotrans-
mitter receptor antibodies.
SS is a chronic autoimmune multisystem disease.
The cornerstones of the disease are dry eyes and mouth
leading to keratoconjunctivitis sicca and xerostomia,
respectively, which are consequences of a dramatic
decrease in the tear or saliva production, respectively.
Further exocrine glands (including nasal, bronchial,
vaginal glands etc.) and other tubulo-epithelial
structures (i.e. biliary tree, renal canaliculi, broncho-
pulmonary system, thyreoid gland) are also frequently
affected. The chronic autoimmune process often
leads to immune-complex mediated manifestations,
including vasculitis, neuritis, glomerulonephritis, and
eventually may evolve into lymphoma, which is
approximately 40 times more common than in the gen-
eral population [1].
The diagnostic hallmark of SS is the demonstra-
tion of a focal lymphocytic infiltrate in the salivary
glands. A peculiar finding in SS is that a critically
low exocrine function is associated with a seemingly
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modest glandular destruction, where glandular areas
infiltrated with lymphocytes are separated with exten-
sive areas of histologically normal salivary gland tissue
[2]. This finding raises the obvious hypothesis that
the loss of glandular function is not merely a direct
consequence of the destruction of the secretory sys-
tem, but, to a certain extent, also of a functional
inhibition of fluid secretion. Inspired by the exam-
ple of Chagas’ disease, a chronic parasitic infection
caused by Tripanosoma cruzi, in which chronic auto-
nomic dysfunction develops mediated by antibodies
directed to beta-adrenergic and cholinergic receptors
[3], Bacman et al. were the first to demonstrate that
immunoglobulin-G (IgG) from SS patients are able to
react with the mAChR of rat parotid gland [4]. These
antibodies have been found to inhibit the binding of
a cholinergic agonist to mAChR in a non-competitive
manner, and to increase the phosphoinositide turnover
and decrease the cAMP levels. These findings were
confirmed in vivo in the elegant experiments of Robin-
son et al.: various knock-out strains of the non-obese
diabetic (NOD) mouse (a model of SS) were stud-
ied, and they found that the NOD-Ig-null mice had
preserved salivary flow despite the salivary gland
destruction and lymphocytic infiltration identical to
that seen in wild-type NOD-mice, and the salivary
flow became severely diminished when IgG from SS
patients was infused in these mice [5]. Moreover,
the IgG fraction responsible for the elicitation of the
salivary dysfunction was identified to competitively
inhibit the action of a mAChR agonist. These findings
suggest that antibodies that block cholinergic neuro-
transmission are present in the sera of SS patients,
and these antibodies are necessary for the evolution
of salivary gland hypofunction in an animal model
of SS.
The first human experimental data on a parasympa-
thetic dysfunction derive from our experiments using
the skin microcirculation as a model of the cholinergic
innervation. We examined the dilatation of cutaneous
vessels in response to the intracutaneous administra-
tion of a cholinergic agonist [6] and we observed
a significantly impaired microvascular reaction to
cholinergic stimulation in SS patients. In fact, exactly
half of the patients proved to be totally unrespon-
sive. We speculated that an autonomic neuropathy
is unlikely to be the cause of this finding, because
the cholinergic agonist was administered directly into
the target organ. The role of inflammatory media-
tors was also considered unrealistic, as the examined
organ was located distinct from the involved glands.
A dysfunction at the receptor or post-receptor level
of signal transduction was therefore presumed, and
we suggested that autoantibodies that react with the
acetylcholine receptors may be responsible for the
unresponsiveness to cholinergic stimuli in SS.
FUNCTIONAL STUDIES ON ANTI-mAChR
ANTIBODIES IN SS
Further characterisation of the putative anti-mAChR
antibodies were carried out in two major pathways:
1) functional studies including in vivo experiments
on animal models, and functional assays on various
cell lines or tissues and 2) the immunodetection and
the determination of the epitope-specificity of these
autoantibodies.
Further experiments on NOD mice provided quite
convincing confirmation of the strong impact of anti-
m3AChR antibodies on the pathogenesis of the salivary
dysfunction in this model. Nguyen et al. tested the
influence of the administration of various mono-
clonal antibodies on the saliva flow in NOD-scid
mice [7]. Due to the scid-mutation, these mice retain
their capability of saliva production. The infusion
of monoclonal antibodies to the subtype-3 mAChR
(m3AChR) – the functionally dominant one of the 5
known mAChR subtypes in the salivary and lachry-
mal glands – resulted in a marked reduction of
saliva flow, whereas anti-La (a diagnostic marker of
SS), anti-parotid secretory protein antibodies had no
impact on the saliva production. Another group trans-
ferred splenocytes from m3AchR–/– mice immunised
with murine m3AChR-peptides into Rag1–/– mice.
Saliva production decreased and a marked infiltra-
tion of inflammatory cells (predominantly Th1 and
Th17 CD4+ T-helper cells) evolved in the salivary
glands. When only CD3+ T-lymphocytes were trans-
ferred, the above-mentioned sialadenitis did develop,
but saliva production remained intact indicating that
B-cell-derived factors are indispensable for the evolu-
tion of the full clinical picture of the disease in mice
[8].
Microfluorimetry, patch-clamp and immunofluores-
cence confocal microscopy studies have consistently
proved, that IgG from SS patients inhibit the
cholinergic agonist-evoked intracellular calcium-
accumulation, K+ and Cl– channel activation in both
rodent and human salivary gland cells [9–11]. This
action is mediated by the m3AChR. This selectivity
is further supported by the finding that other path-
ways, such as the adenosine-receptor-mediated cellular
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consequences of the impaired acetylcholine-induced
salivary acinar cell-activation include a defective
water secretion, as evidenced by the impairment of
carbachol-induced aquaporin-5 translocation in human
salivary gland cells pre-incubated with SS IgG [11].
The importance of this finding is highlighted by the
fact that reduced aquaporin-5 concentrations at the
apical membrane of the acinar cells in the lachrymal
and salivary glands (due to impaired trafficking of the
molecule to the cell surface) are thought to decrease
tear and saliva production in SS patients [12]. Fur-
ther cellular alterations in SS IgG-pretreated cells are
a diminished cytoskeletal reorganisation of -fodrin,
a process that normally takes place after cholinergic
stimulation. Anti-fodrin antibodies have been found
to be relatively specific of SS, although, due to its
low sensitivity, it has not become routinely used. Anti-
m3AChR antibodies have been shown to induce further
alterations in the salivary glands: m3AChR-specific
IgG affinity-purified from SS patient sera stimu-
lated the production of matrix-metalloproteinase-3 in
submandibular gland cultures [13]. This effect was
mediated by prostaglandin-E2 via phospholipase-A2
and cyclooxigenase-2 activation. These results raise
the possibility that anti-m3AChR antibodies may par-
ticipate in the structural destruction of the exocrine
glands as observed in SS.
The inhibition of parasympathetic neurotransmis-
sion by SS-IgG has also been confirmed in bioassays
using smooth muscle cells as targets. Using isolated
bladder strips, Waterman et al. revealed that IgG from
SS patients inhibited the smooth muscle contraction
evoked by either parasympathetic nerve stimulation
or by a cholinergic agonist [14]. Sera from patients
with various autoimmune connective tissue diseases
with sicca symptoms also demonstrated this inhibition,
while from those without sicca symptoms did not. Con-
trol experiments suggested that this inhibitory effect
was mediated through the muscarinic receptor. In a
further set of examinations, SS-IgG also inhibited the
neuronally mediated or agonist-evoked gastrointesti-
nal motility in a m3AChR-dependent fashion as evi-
denced by the disrupted contractility of isolated muscle
strips or whole-organ colonic motility in mice [15].
An important question is the response of the sali-
vary acinar cells to chronic exposure to anti-m3AChR
antibodies as it putatively happens in the human
disease. Indeed, Beroukas et al. found the expres-
sion of m3AChR to be up-regulated in SS salivary
glands as compared with controls [16]. In contrast, a
recent publication reports on the induction of receptor-
internalisation in response to long-term incubation
with SS IgG in salivary gland acinar cells [17]. The
process of receptor-internalisation is a well-known
phenomenon during chronic agonist-exposure, and the
internalised receptors later either recirculate to the sur-
face or are degraded. In the study of Jin and colleagues,
the amount of both surface and intracellular m3AchR
decreased due to progressive receptor phosphorylation,
clathrin-coat dependent internalisation and probably a
subsequent intracellular degradation of m3AChR in
response to 90 minutes’ exposure to anti-m3AChR
positive SS serum. Moreover, it was demonstrated
in NOD-mice (in which anti-m3AChR antibodies are
present) that cholinergic agonist-evoked responses are
diminished as modelled by the contraction of isolated
bladder strips as compared with preimmune NOD-
mice or control strains [18]. This finding was consistent
with receptor desensitisation due to the chronic stim-
ulation by circulating anti-m3AChR antibodies. All
these findings provide interesting mechanisms by
which autoantibodies reactive with autonomic ner-
vous system receptors could exert their action, but the
long-term effects of anti-m3AChR antibodies on the




As it could be seen, several results have emerged
concerning the functional changes in response to IgG
obtained from SS patients or relevant experimen-
tal animals, but, obviously, studies on anti-m3AChR
antibodies would require the reliable isolation and
identification of these antibodies. A convincing proof
of their pathogenetic role would be the development
of a validated immunodiagnostic method to test the
prevalence, concentration, and epitope-specificity of
these autoantibodies, what would ultimately lead to
a useful diagnostic test in the clinical practice. How-
ever, the results of these efforts have remained quite
controversial so far.
The first report suggesting the existence of antibod-
ies to the acetylcholine-receptor utilised an isotopic
receptor binding assay to examine the reaction of rat
salivary gland homogenates with SS sera [4]. The
first ELISA method for the detection of anti-m3AChR
antibodies was reported by Bacman et al, who found
anti-m3AChR antibodies in the majority of the exam-
ined primary and secondary SS patients, but not in
healthy controls or rheumatoid arthritis patients [19].
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disease - in which the immunodominant epitope is
localised at the second extracellular loop, which also
contains the ligand-binding region – they selected a 25-
mer peptide from this section of the molecule, and used
it as an antigen in a peptide-based ELISA. However,
a few years later, it turned out that this peptide was
actually a peptide sequence of the human m4AChR
[20]. Cavill and co-workers tested both the m3AChR-
peptide with the correct amino-acid sequence and
the erroneously chosen m4AChR-peptide and failed
to demonstrate a consistent immunoreaction with
either of the peptides despite several trials of lab-
oratory methodological approaches [20]. Dawson
et al. later reached the same conclusion after the neg-
ative results of multiple immunological approaches,
including Western blot and spot-blot tests of m3AChR-
transfected Chinese hamster ovary cell membrane
fragments or a whole cell ELISA in which these cells
were applied as antigen [21]. A subsequent report,
however, contradicted these negative conclusions: Gao
and co-workers succeeded in demonstrating the pres-
ence of anti-m3AChR antibodies in 9 of 11 SS patients
by using a fairly sophisticated ELISA system in which
the antigen was a Chinese hamster ovary cell line
transfected with a recombinant human m3AChR pro-
tein propagated in hygromycin [41]. To complicate the
issue further, another two articles from this period both
reported positive results on anti-m3AChR antibodies
albeit in relatively small proportions of SS patients
[16/95 and 11/122, respectively] [22, 23] following the
use of a peptide ELISA with the same 25-mer pep-
tide as that with which Cavill et al. were unable to
detect anti-m3AChR antibodies in SS patients. The
epitope-specificity also remains elusive as the third
extracellular epitope was also suggested to be an
immunodominant region of the molecule [24] with
surface plasmon resonance studies, and others have
also found an immunoreaction between the N-terminal
region, the 1st and 3rd extracellular loop and SS sera,
although with variable functional consequences [25].
To circumvent the difficulties with linear synthetic
peptides, cyclic peptides were also generated corre-
sponding to various segments of the m3AChR with
some degree of reactivity with SS or other autoimmune
sera [26]. But after extensive examinations from Illei’s
group using several forms of various m3AChR-derived
peptides, the authors concluded that peptide-based
ELISAs are not sensitive and specific enough to detect
m3AChR autoantibodies in serum from patients with
SS [27].
We have also utilised multiple ELISA methods
in order to test whether the putative anti-m3AChR
antibodies actually react with the human antigen, and
to assess the prevalence of these autoantibodies in
SS and various healthy and disease control popula-
tions. In view of our previous experience with peptide
ELISAs [28], we hypothesised that an epitope that
is possibly conformational and not linear can better
preserve its immunogenic characteristics in a system
that provides a protein microenvironment for the anti-
genic sequence rather than using the peptide itself, as
in ELISAs involving relatively short synthetic pep-
tides as antigen. Accordingly, through the use of
computer software, we predicted the immunodomi-
nant amino acid sequence of the m3AChR molecule,
and on this basis, we selected a 16-mer peptide at
the 2nd extracellular loop of the m3AChR as an
antigen. We then constructed a recombinant fusion
protein containing this peptide fused with glutathione-
S-transferase (GST), and compared the performances
of ELISA systems using this antigen and the same pep-
tide chemically synthesised. The peptide ELISA posed
numerous methodological difficulties and, although we
detected anti-m3AChR213-228 antibodies in a high
proportion of primary SS patients, we concluded that
this mode of antigen presentation is rather problem-
atic and not fully reliable [29]. However, with the
ELISA in which the recombinant GST-m3AChR213-
228 fusion protein was used as antigen, we were able
to demonstrate specific and reproducible binding reac-
tions with SS sera, indicating the presence of anti-
m3AChR213-228 antibodies in 90% of the primary SS
patients and in none of the controls [30]. Moreover, the
incidence and mean levels of these antibodies were sig-
nificantly lower in patients with rheumatoid arthritis,
systemic lupus erythematosus or undifferentiated sicca
syndrome.
Our experience during these measurements con-
firmed that it is a rather problematic task to develop an
ELISA system for the detection of anti-m3AChR anti-
bodies, which explains the conflicting results obtained
earlier. We speculated that the probable immunogenic
epitope of the antigen should be a conformational epi-
tope, and the appropriate conformation provided by a
protein microenvironment, such as a GST-fusion pro-
tein structure, is necessary for the assumption of the
natural conformation required for the immunogenicity
of the antigen. This may be in part a consequence of
the two cysteine residues within the epitope, and our
experiments suggested that oxidation or the dimerisa-
tion of the peptide may lead to crucial changes in its
applicability as an antigen [29]. This may also explain
the markedly lower levels of anti-m3AChR positivity
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with the methods in which the epitope was “embedded”
in a more natural microenvironment, as in the cases
with cell-based [28] or GST-bound [29, 30] antigen
presentation.
Even though the presence of circulating m3AChR-
specific antibodies has not been convincingly proven,
a further confirmation of their pathogenicity would
be to demonstrate the presence of anti-m3AChR anti-
bodies in the target organ, i.e. the salivary glands.
As polyclonal SS IgG is expected to bind extensively
to the salivary tissue at multiple localisations, the
verification of the specific binding of serum IgG to
the m3AChR would require ultrastructural studies in
which the receptor is clearly identifiable. We therefore
used electron-microscopic immunocytochemistry, and
were able to demonstrate the binding of IgG in SS
sera to the postsynaptic membrane of the junction of
the end-plates of cholinergic nerves on human salivary
gland acinar cells, and also in vivo bound IgG in SS sali-
vary gland biopsy specimens at the above-mentioned
localisation corresponding to the m3AChR [31]. These
findings seem to support that anti-m3AChR antibodies
are not only detectable in the sera of SS patients, but
they are also able to react with their putative autoanti-
genic targets.
ANTI-m3AChR ANTIBODIES IN SYSTEMIC
SCLEROSIS (SCLERODERMA)
SS does not appear to be the only disease where
anti-m3AChR antibodies might be relevant. Another
systemic autoimmune illness, systemic sclerosis (SSc),
characterised by excessive diffuse skin and soft-tissue
fibrosis, and a dramatic microcirculatory disturbance
leading to ischaemic damage may be another exam-
ple. The progressive fibrotic process also involves the
lungs, heart and gastrointestinal tract, and the lat-
ter was blamed for the marked hypomotility, rigidity
and distension of the whole gastrointestinal canal,
most prominently of the oesophagus, the colon and
the rectum. However, Goldblatt et al. have revealed
that the sera of SSc patients contain immunoglobulins
that block the cholinergic agonist-evoked contraction
of mouse colon strips in an apparently m3AChR-
mediated fashion [32]. Later, Singh and co-workers
confirmed these findings with the use of isolated rat
colonic smooth muscle strips [33]. These results raise
the possibility that a cholinergic dysfunction is also
partly responsible for the dramatic loss of gastroin-





Nicotinic acetylcholine receptors localised in auto-
nomic ganglia have been found to be a target of
antibodies in patients with autonomic nervous system
dysfunction. These symptoms range from orthostatic
hypotension, gastrointestinal hypomotility and anhy-
drosis (loss of perspiration) to a debilitating collapse of
autonomic regulation called pandysautonomia. These
symptoms usually arise as a separate entity whereby
autonomic dysfunction is not explained by the com-
mon causes of neuropathy including diabetes mellitus,
toxic or degenerative causes. An autoimmune response
targeting the autonomic ganglia has been proposed
as the underlying mechanism, and in a large series
of 15 000 patients tested, 155 were found to have
anti-ganglionic nicotinic acetylcholine-receptor anti-
bodies [34] Thirty percent of these patients had an
underlying malignancy, and the presence of these anti-
bodies was therefore considered as a paraneoplastic
phenomenon. None of the SS- or systemic lupus ery-
thematosus patients tested proved to be positive to
these antibodies, and altogether there is only one
SS-patient reported in the literature with ganglionic
acetylcholine receptor antibody-positivity and an asso-
ciated autoimmune autonomic ganglionopathy [35],
thus these antibodies do not seem to play a major role
in systemic autoimmune diseases, but their pathogenic
role in cancer-associated or idiopathic autoimmune
autonomic failure has been confirmed both in humans
and animal models.
In addition to anti-m3AChR, antibodies with other
specificities were also isolated from Chagas’ dis-
ease patients’ sera, namely anti-beta-1 adrenergic
(anti-beta-1AR) antibodies [36]. Subsequently, these
antibodies were also found in the sera of 25–90%
of patients with dilated cardiomyopathy, a common
and potentially fatal myocardium disease with mul-
tiple potential aetiologies and no established cure
[37]. These antibodies were found to bind to the 2nd
extracellular loop of the beta-1AR in most studies –
similarly to anti-m3AChR – but the 1st extracellular
loop was also proposed by other authors [38, 39]. Anti-
beta-1AR antibodies are supposed to have an agonist
or partial agonist activity on the receptor, leading to
cAMP-accumulation, membrane-potential alterations
that give rise to fatal arrhythmias, and myocyte degen-
eration or hypertrophy [40, 41]. The prevalence and
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receptors has nicely been reviewed by Nussinovitch
and Shoenfeld [42].
CONCLUDING REMARKS
In sharp contrast to a wealth of interesting exper-
imental data on the functional characteristics of all
the three above-mentioned antibodies, it seems that
the immunological detection of antireceptor antibodies
is rather problematic. This obviously greatly impedes
the convincing confirmation of the pathophysiolog-
ical relevance of this mechanism in a number of
serious diseases, and also hampers the assessment
of their clinical importance and the development of
routinely available tests for their detection. As con-
ventional ELISA methods seem to fail in the hand of
most of the groups, highly sophisticated techniques
involving functional components have been introduced
in specialised centres, including the assessment of
receptor-mediated signaling by measuring cAMP by
fluorescence-resonance energy transfer for the detec-
tion of anti-beta-1AR [43], and radioligand-binding
assay on neuroblastoma cell line-derived nicotinic
acetylcholine receptors by means of an Iodine125
labelled receptor agonist [44]. These problems indi-
cate that he antigenic determinant of neurotransmitter
receptors may be a particularly sensitive region in
terms of antigenic structure, especially in macro-
molecules embedded in the lipid-bilayer of the plasma
membrane with 7 molecular folds, or that the amount
of antireceptor antibodies is so low in the serum
that the standardization of the signal-noise parame-
ters of immunodiagnostic tests may be accompanied
by utmost difficulties.
The binding of these putative autoantibodies to their
receptors may lead to either a receptor agonist or
antagonist response. Either the deprivation of crucial
neural stimuli or the recapitulation of the action of the
physiological ligand in the form of a perpetual “over-
stimulation” will lead to the deviation of intracellular
signal-transduction pathways, progressive subcellular
alterations, and later tissue remodelling, and these will
not only interfere with the function of these visceral
organs but may eventually lead to permanent organ
destruction.
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